Please assess the completion status of the following clinical trial:

Trial Title: Safety and Tolerability of the PRO-174 Versus Sophixín Ofteno®, on the Ocular Surface of Healthy Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent.~* Systemically and ophthalmologically healthy subjects evaluated during the clinical history.~* Age between 18 to 45 years.~* Both genders.~* Blood tests (complete blood count, blood chemistry of three elements and liver function tests) within normal parameters specified by the reference laboratory with a lower and upper margin of 10%.~* Vital signs within normal parameters. (Vital signs at rest: blood pressure ≤ 139/89 mmHg, heart rate 60 -100 beats per minute and respiratory rate of 12-24 breaths per minute).~* Visual capacity 20/30 or better, in both eyes.~* Intraocular pressure ≥11 and ≤ 21 mmHg.~Exclusion Criteria:~General criteria~* Subjects with a history of hypersensitivity to any of the components of the research products.~* Subject users of topical ophthalmic medications of any pharmacological group.~* Subject users of medication by any other route of administration.~* Pregnant or lactating women.~* Women of childbearing age, who do not ensure a hormonal contraceptive method or intrauterine device during the study period or without a history of bilateral tubal obstruction, oophorectomy or hysterectomy; as fertile age we understand women who have not had their menopause, defined as 12 months since the last menstruation in women over 40 years.~* Subjects with participation in clinical research studies 90 days prior to inclusion in the present study.~* Diagnosis of liver disease or elevation to three times the normal upper value of any of the following liver enzymes: aspartate transferase (AST), alanine transferase (ALT) or bilirubin.~* Inability to attend or answer the evaluations made in each of the visits.~* Positive smoking (specified as cigarette consumption regardless of amount and frequency)~* Positive alcoholism (specified as the consumption of alcoholic beverages, regardless of quantity and frequency, during the study intervention period).~* Contact lens users.~* An occlusive iridocorneal angle, defined as a trabecular mesh visible at less than 90 ° from the angular circumference to gonioscopy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- PRO-174 (Type: EXPERIMENTAL): Active ingredient: Levofloxacin 0.5%~o Dosage: 1 drop in both eyes, 8 times a day during the waking period
- Sophixín Ofteno® (Type: ACTIVE_COMPARATOR): o Dosage: 1 drop in both eyes, 8 times a day during the waking period

Based on this trial design, predict the completion outcome and termination type (if applicable).